- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute, discusses what's needed from a policy perspective to ensure access to next-generation sequencing (NGS) tests.
Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute, discusses what's needed from a policy perspective to ensure access to next-generation sequencing tests.
Transcript
As next-generation testing becomes more important with a growing amount of approved targeted therapies, what is needed from a policy perspective to ensure access to these tests?
Access to these tests and getting the various stakeholders together. if I were a payer at an insurance company, my question wouldn’t be whether I approve the testing or not, it would really be how could you be prescribing this new therapy, this relatively expensive therapy, without having a molecular profile on the patient. I think much like we’ve had legislation with regard to access to clinical trials, this sort of national education that cancer patients should be access agnostic to being able to getting a test performed, would be key.
A good first step has been the FDA approving some of these tests and then Medicare providing reimbursement. So, I feel optimistic that were moving in a direction where we’re going to begin to get policy makers across the country, the physicians across the country, to understand this is a critical piece of information cancer patients should know.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
